Initial Statement of Beneficial Ownership (3)
February 10 2021 - 6:00PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Foresite Capital Management III, LLC |
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/5/2021
|
3. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ACRS]
|
(Last)
(First)
(Middle)
600 MONTGOMERY STREET,, SUITE 4500 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
SAN FRANCISCO, CA 94111
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 1954904 | I | See Footnote (1) |
Common Stock | 3399034 | I | See Footnote (2) |
Common Stock | 1258243 | I | See Footnote (3) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | The shares are owned directly by Foresite Capital Fund III, L.P. ("Fund III"). Foresite Capital Management III, LLC ("FCM III") is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
(2) | The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
(3) | The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Foresite Capital Management III, LLC 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO, CA 94111 |
| X |
|
|
Foresite Capital Fund III, L.P. 600 MONTGOMERY STREEET SUITE 4500 SAN FRANCISCO, CA 94111 |
| X |
|
|
Foresite Capital Management IV, LLC 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO, CA 94111 |
| X |
|
|
Foresite Capital Fund IV, L.P. 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO, CA 94111 |
| X |
|
|
Foresite Capital Management V, LLC 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO, CA 94111 |
| X |
|
|
Foresite Capital Fund V, L.P. 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO, CA 94111 |
| X |
|
|
Tananbaum James B. 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO, CA 94111 |
| X |
|
|
Signatures
|
FORESITE CAPITAL MANAGEMENT III, LLC, By: /s/ James B. Tananbaum, Managing Member | | 2/10/2021 |
**Signature of Reporting Person | Date |
FORESITE CAPITAL FUND III, L.P., By: Foresite Capital Management III, LLC, Its: General Partner, By: /s/ James B. Tananbaum, Managing Member | | 2/10/2021 |
**Signature of Reporting Person | Date |
FORESITE CAPITAL MANAGEMENT IV, LLC, By: /s/ James B. Tananbaum, Managing Member | | 2/10/2021 |
**Signature of Reporting Person | Date |
FORESITE CAPITAL FUND IV, L.P., By: Foresite Capital Management IV, LLC, Its: General Partner, By: /s/ James B. Tananbaum, Managing Member | | 2/10/2021 |
**Signature of Reporting Person | Date |
FORESITE CAPITAL MANAGEMENT V, LLC, By: /s/ James B. Tananbaum, Managing Member | | 2/10/2021 |
**Signature of Reporting Person | Date |
FORESITE CAPITAL FUND V, L.P., By: Foresite Capital Management V, LLC, Its: General Partner, By: /s/ James B. Tananbaum, Managing Member | | 2/10/2021 |
**Signature of Reporting Person | Date |
By: /s/ James B. Tananbaum | | 2/10/2021 |
**Signature of Reporting Person | Date |
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024